Related Experiment Videos
Interferon alfa-2a therapy for airway hemangiomas
L A Ohlms1, D T Jones, T J McGill
1Department of Otolaryngology, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115.
The Annals of Otology, Rhinology, and Laryngology
|January 1, 1994
Summary
Recombinant interferon alfa-2a offers a new treatment for infants with life-threatening airway hemangiomas. This therapy shows promise for extensive lesions unresponsive to traditional treatments like steroids and laser therapy.
Area of Science:
- Pediatric Otolaryngology
- Medical Oncology
- Regenerative Medicine
Background:
- Infantile airway hemangiomas can cause life-threatening obstruction.
- Conventional treatments like corticosteroids and laser therapy are not always effective for extensive lesions.
Observation:
- This study evaluated recombinant interferon alfa-2a in 15 infants with severe airway hemangiomas.
- All patients had previously failed standard therapies.
- Lesions involved multiple upper airway sites, including the trachea and mediastinum.
Findings:
- Eleven of 15 patients showed positive outcomes after interferon alfa-2a therapy.
- Four patients had ongoing lesion resolution with the treatment.
- The therapy was effective for extensive, life-threatening airway hemangiomas.
Implications:
- Recombinant interferon alfa-2a represents a viable therapeutic option for difficult-to-treat infantile airway hemangiomas.
- Consideration of interferon alfa-2a is warranted for patients unresponsive to conventional treatments.
- This approach may improve outcomes for infants with severe airway compromise.